Baillie Gifford trim Alnylam Pharmaceuticals, Inc.
Baillie Gifford trim $1.3B of disclosed value in Alnylam Pharmaceuticals, Inc..
Signal
Investor Move
Action
Trim
Capital
$1.3B disclosed value
Why it matters
This action comes from parsed SEC 13F holdings and highlights where tracked institutional capital changed materially versus the previous comparable filing period.